Supplement

Design of cystatin C chimeric peptides
Chimeric peptide Cys1 was generated by removing the first amino acid and making two substitutions, W3A and Q10E, in α-factor. Removing the W1 has been reported to not reduce biological activity of the ligand 1 , and the W3A substitution has been reported to show a reduction, but not complete loss in affinity 2 . We anticipated Q10E would be a low risk mutation, as both amino acids are polar and similar structure.
Chimeric peptide Cys2 was generated by making a mutation at H2 to Cys1. Since H2 in α-factor has been reported to be crucial in receptor activation [1] [2] [3] , we perceived any alteration to this position as a high risk mutation, and elimination of this position was the only change made to form ligand Cys2.
To create peptide Cys3 from Cys2, we made two substitutions: A3D and L4F. We expected A3D to be a higher risk substitution as both amino acids differ in size, polarity, and hydrophobicity. Consequently, we paired this substation with L4F, where both amino acids are hydrophobic and closely related in structure.
In an effort to reduce risk by pursuing multiple pathways, chimeric peptide Cys4 was created by altering peptide Cys2 with the following substitutions: A3D, K5A, and P6V. The K5A substitution was reported to be active, though slightly less so, in a full length version of α-factor 2 . We anticipated that the P6V substitution would be of moderate risk as it occurs in the region of the ligand known as the 'bend' region, characterized by the presence of a type-II beta turn 2 . Though the P6V substitution disturbs the type-II beta turn, it does not completely eliminate it 4 .
The cystatin C peptide Cys7 was created by a combining substitutions from chimeric peptides Cys3 and Cys4 with substitutions in the final three amino acids, also known as the binding region. Replacement of amino acids in the binding region is known to reduce ligand affinity 2 . Though changing all three amino acids at once is high risk, we believed we could overcome limitations of a weakly binding peptide ligand by using relatively high concentrations of ligand.
Analysis of mutations in receptors
Receptors Cys1H4 and Cys1H5 contained mutations M54I and M54I/C59S, respectively, which lie in the first transmembrane region. Mutation M54I specifically has been reported to give Ste2p the ability to respond to the synthetic α-factor variant desTrp 1 [Ala 3 ,Nle 12 ]α-factor 5 , which is similar in size and sequence to the chimeric Cys1 ligand. Additionally, M54 lies in a region of transmembrane helix 1 which is previously known to directly interact with peptide residues Q10-Y13 6, 7 . Receptors Cys2K2 and Cys2K3 gained mutations M218K and M218T/K225T, respectively, in the fifth transmembrane region, the relative motion of which is required for receptor activation 8 . In the context of the native Ste2p, M218T on its own is a neutral mutation, and residue 218 is believed to interact with residues on the third transmembrane region. Interestingly, M218T can rescue receptor functionality when paired with function-ablating mutations in the third transmembrane region 9 , and a mutation in this position may help the receptor cope with otherwise destabilizing mutations. The K225C mutation ablates functionality of the native Ste2p receptor 10 , so it is noteworthy that a substitution to a similarly nucleophilic residue (K225T) did not ablate receptor functionality here. Receptor Cys2K2 contains the Q272Y mutation in the third extracellular loop. Though the third extracellular loop has been shown to be important for ligand recognition 11 , this mutation was eventually lost during the course of our directed evolution. Receptor Cys2K3 gained the N158Y mutation in the second intracellular loop.
Receptors Cys4L3 is truncated on the C terminal tail (Y320X), which contains multiple ubiquitination sites necessary for receptor endocytosis 12 and signal desensitization 13 following ligand stimulation. Thus, we predict receptor Cys4L3 to have prolonged signaling after ligand stimulation. Additionally, receptor Cys4L3 contains the Y26F mutation located in the N terminus, which has been reported to undergo a conformational change upon ligand binding and be involved in receptor dimerization 14 . Given the chemical similarities between arginine and lysine, we propose that the R74K mutation gained in Cys4L3 is neutral. Receptor Cys4L3 also contains the N158F mutation in the second intracellular loop and the T167R located on the border of the second intracellular loop and the fourth transmembrane region.
Compared to parent receptor Cys4L3, receptors Cys5R2 and Cys5R7 contain a further mutation at position 158. Interestingly, position 158 is mutated throughout the directed evolution pathway from an amide residue (N) to increasingly hydrophobic residues (Y and F). Receptor Cys5R9 contains the hydrophobic substitution T167R on the border of ICL2 and the fourth transmembrane region. We hypothesize that these hydrophobic changes in the second intracellular loop may assist with G-protein coupling as the second intracellular loop is accessible to the G-protein 15 . In the context of the native Ste2p receptor, residues 156-162 can be removed without drastically affecting response to the native α-factor 16 . However, our findings support both the formation of a hydrophobic pocket by intracellular loops to interact with the G-protein 15 , and the importance of the intracellular loops in mediating signaling from C-terminal truncated receptors 17 . Because the C-terminus interacts with the G-protein 18 , C-terminal truncated receptors may become more dependent on intracellular loop contacts with the G-protein. Residue 158 is accessible to the G-protein 15 , and the role of the second intracellular loop in coupling to Gproteins in other GPCR families is documented [19] [20] [21] . Finding beneficial mutations far from the putative binding site is not surprising as it has been demonstrated that Ste2p can be evolved to detect non-native peptides through the alteration of interactions with other proteins in the signaling network 22 . Receptor Cys5R2 has the F55L mutation. Position 55 has been implicated in ligand specificity and signal transduction 23 . Compared to parent receptor Cys2K3, receptor Cys5R7 contains mutations D3N, L228F, and S325X. The effects of a premature truncation have been described above, and due to the hydrophobicity of both leucine and phenylalanine, we propose that the L228F mutation may be neutral. We hypothesize that the increase in hydrophobicity from aspartic acid to asparagine may assist in ligand binding or affect receptor dimerization. Finally, receptor Cys5R9 contains the S121R substitution in the first extracellular loop. This region has been implicated in regulating specificity 11 , and mutations in this region have been shown to compromise signal transduction 24 . Interestingly, no mutations were gained in the second or fourth transmembrane regions. It is believed that there are common underlying mechanisms between class A GPCRs, typically represented by the rhodopsin receptor, and class D GPCRs, of which Ste2p is a member 25 . The second or fourth transmembrane regions, which are believed not to change structurally during receptor activation in class A GPCRs 25 , may provide similar structural support in class D GPCRs. Additionally, the two receptor classes share highly conserved microdomains on the sixth and seventh transmembrane regions. That we did not observe any mutations in these transmembrane regions may be explained by the conservation of these regions. We were surprised that we did not observe mutations in the second extracellular loop as this region has been implicated in signaling and specificity 26 . To summarize the course of evolution, we first observed a mutation that likely affected the binding pocket (M54I), then mutations that are likely to be responsible for global stability (M218K, M218T, K225T), followed by mutations that may affect interaction with other signaling network proteins (truncations, T167R, N158Y, N158F). We hypothesize that further directed evolution at lower peptide concentrations and directed evolution against α-factor or earlier chimeric peptides in the pathway will reveal mutations important for sensitivity and specificity.
Specificity can be evolved
Supplementary Figure 1-Receptors can be counter-sorted against alpha-factor to increase specificity towards the target ligand-Variant 56.
After demonstrating the ability to evolve sensitivity for a range of peptides we next tested if specificity could be evolved for peptide Variant 56 (sequence: WHYLQLKPGQPMY), which contains a single-amino acid substitution compared to α-factor. In round 1, error prone PCR was performed on Ste2p to create a library of mutant receptors that were subjected to sorting with 100 nM Variant 56. The best mutant isolated from this sort was re-mutagenized to create a new library. The new library was sorted in round 2 with 100 nM Variant 56, and did show an improvement in detecting Variant 56 (panel a). In round 3, the sorted library from round 2 was screened for lack of activity for α-factor by collecting receptors that did not fluoresce in the presence in 100 nM α-factor. Round 3 mutants show a decrease in ability to sense α-factor (panel b) but are preferentially activated by Variant 56 (panel c). Fluorescence was measured on a BioTek plate reader at approximately 30 minute intervals over the course of 3.5 hours. Fluorescence response is yeGFP/mKate normalized by the yeGFP/mKate value of WT Ste2 after subtracting for auto-fluorescence of CSM-Ura media. mKate was measured at 585 nm excitation and 615 nm emission and yeGFP measured at 485 nm excitation and 528 nm emission. . Next, we calculated the evolutionary step size for each of the 8 designed peptides using the BLOSUM62 matrix 29 to determine amino acid substitution costs and normalizing by peptide length (see Methods). The step size is a measure of the amount of evolutionary change per amino acid in a peptide. We screened our Ste2p library to find mutants sensitive to the 8 peptides. Supplementary Figure 6 shows the sensitivity of evolved receptors from the Ste2p library that responded to peptides of different step sizes. Peptides that were very similar to α-factor, as indicated by a small step size, produced mutant receptors with high sensitivity (low EC 50 value). More distant peptides produced receptors with weak or no detectable response up to 10μM, the highest concentration tested. Calculated step size was fit to the experimental EC 50 results. We estimated a maximum permissible step size that would yield a receptor with an EC 50 below 10μM to be 5.07. Notably, the calculated step size from α−factor directly to Cys7 was 8.31, which accounts for our failure to evolve a receptor for Cys7 directly from Ste2p.
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Stochastic Fluorescence in yeast strains
Supplementary Figure 7 -Yeast strains used for this study display inherent stochasticity in response to ligand stimulation. A population of WT Ste2p receptor exposed to 1 µM α-factor peptide is shown overlapping a population of untreated WT Ste2p. There is a segment of the treated population that does not fluoresce even though 1 µM α-factor is a saturating amount of ligand. While this issue is easily overcome with a population containing only one receptor type, the inherent stochasticity becomes a larger problem when evaluating a library of mutant receptors. To overcome this inherent stochasticity during sorting, we performed multiple round of enrichment while setting the sorting gate to accept some false positive mutants to avoid the loss of false negative receptors.
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